Vassilios Aslanis

Vassilios Aslanis is an experienced professional in the field of Clinical Pharmacology. Vassilios has held various leadership roles in major pharmaceutical companies. From 2021 to the present, they have served as the Head of Clinical Pharmacology at Galecto, Inc., where they are responsible for establishing Clinical Pharmacology throughout the organization and driving the global strategy for the Galecto pipeline.

Prior to Galecto, Inc., Aslanis worked at Ipsen from 2018 to 2021 as the Head of Clinical Pharmacology & Clinical Sciences. In this role, they managed a team of Clinical Pharmacologists and was accountable for implementing Clinical Pharmacology and Translational Medicine components for Oncology, Rare Diseases, and Systemic Radiation Therapy projects.

From 2013 to 2018, Aslanis held positions at Novartis Oncology. First, as an Associate Director in Translational Medicine, they led the Clinical Pharmacology and PKPD development program for small molecules in Oncology and Hematology. Later, as a Manager in Oncology Clinical Pharmacology, they were responsible for the successful transition of in-licensed and acquired assets to Oncology Global Development and played a key role in defining operating processes and study standards.

Aslanis also gained significant experience at Novartis Institutes for BioMedical Research (NIBR) from 2009 to 2013, where they served as a Senior Clinical Pharmacology and PKPD Program Leader. In this role, they represented the Clinical Pharmacology and PKPD Global Program Team on project teams and coordinated activities for the registration dossier. Vassilios was also involved in due-diligence activities and played a role in the development of internal SOPs and processes.

Before joining Novartis, Aslanis worked at Pierre Fabre Group from 2003 to 2009 as a Clinical PKPD Project Manager, leading the Clinical PKPD components of Oncology and Hematology projects. Vassilios also served as a Clinical PKPD representative in workgroups for GCP implementation.

Earlier in their career, Aslanis taught PharmD candidates as a Teacher at Sciences Plus Prépa Santé from 2000 to 2009. Vassilios also worked as a Clinical Pharmacokineticist at IUCT-Oncopole in 2002, where they focused on studying PKPD drug-drug interactions using population PK modeling and conducting bioanalysis of anticancer drugs.

Overall, Vassilios Aslanis has extensive experience in Clinical Pharmacology, with expertise in strategy development, team management, and driving successful drug development programs.

Vassilios Aslanis has a strong education background in the field of pharmacy and sciences. Vassilios earned their Doctorate of Pharmacy (PharmD) from Université Paul Sabatier Toulouse III, where they studied from 1997 to 2003. During this time, they also obtained a Master's degree in Biological and Medical Sciences from the same institution, which they completed from 1998 to 2000.

Prior to their undergraduate studies, Aslanis attended Lycée Franco-Hellénique Eugène Delacroix, where they pursued their high school education in Sciences from 1983 to 1995.

Later on, Aslanis further honed their expertise by completing a Master of Science (MSc) program in Pharmacokinetics and Drug Metabolism at Paris-Sud University (Paris XI) from 2003 to 2004.

Overall, Aslanis has demonstrated a strong dedication to their education, with a focus on pharmaceutical and medical sciences.